• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

吸入型双特异性单域抗体对 SARS-CoV-2 变体的广泛中和作用。

Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibody.

机构信息

MOE/NHC/CAMS Key Laboratory of Medical Molecular Virology, Shanghai Institute of Infectious Disease and Biosecurity, The Fifth People's Hospital of Shanghai, Institutes of Biomedical Sciences, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China.

Shanghai Key Laboratory of Lung Inflammation and Injury, Department of Pulmonary Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, China; Shanghai Engineering Research Center for Synthetic Immunology, Shanghai 200032, China.

出版信息

Cell. 2022 Apr 14;185(8):1389-1401.e18. doi: 10.1016/j.cell.2022.03.009. Epub 2022 Mar 10.

DOI:10.1016/j.cell.2022.03.009
PMID:35344711
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8907017/
Abstract

The effectiveness of SARS-CoV-2 vaccines and therapeutic antibodies have been limited by the continuous emergence of viral variants and by the restricted diffusion of antibodies from circulation into the sites of respiratory virus infection. Here, we report the identification of two highly conserved regions on the Omicron variant receptor-binding domain recognized by broadly neutralizing antibodies. Furthermore, we generated a bispecific single-domain antibody that was able to simultaneously and synergistically bind these two regions on a single Omicron variant receptor-binding domain as revealed by cryo-EM structures. We demonstrated that this bispecific antibody can be effectively delivered to lung via inhalation administration and exhibits exquisite neutralization breadth and therapeutic efficacy in mouse models of SARS-CoV-2 infections. Importantly, this study also deciphered an uncommon and highly conserved cryptic epitope within the spike trimeric interface that may have implications for the design of broadly protective SARS-CoV-2 vaccines and therapeutics.

摘要

SARS-CoV-2 疫苗和治疗性抗体的有效性受到病毒变异的不断出现以及抗体从循环系统扩散到呼吸道病毒感染部位的限制。在这里,我们报告了两种在 Omicron 变异受体结合域上高度保守的区域的鉴定,这些区域被广泛中和抗体所识别。此外,我们生成了一种双特异性单域抗体,该抗体能够在冷冻电镜结构中同时协同结合单个 Omicron 变异受体结合域上的这两个区域。我们证明,这种双特异性抗体可以通过吸入给药有效地递送到肺部,并在 SARS-CoV-2 感染的小鼠模型中表现出出色的中和广度和治疗效果。重要的是,这项研究还揭示了刺突三聚体界面内一个罕见且高度保守的隐藏表位,这可能对设计广泛保护的 SARS-CoV-2 疫苗和治疗方法具有重要意义。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/589a/8907017/eb5299e2de82/figs7_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/589a/8907017/91921f313ba0/fx1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/589a/8907017/299e87850f9c/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/589a/8907017/478947ac66fb/figs1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/589a/8907017/ac889e23fa0e/figs2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/589a/8907017/a64520bff288/figs3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/589a/8907017/92c738afc66e/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/589a/8907017/af819b6bfc41/figs4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/589a/8907017/3527d6ebddfb/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/589a/8907017/5983dc473a68/figs5_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/589a/8907017/c453dad92cca/figs6_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/589a/8907017/ead6264d32d4/gr4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/589a/8907017/665949210b77/gr5_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/589a/8907017/f389f11cd301/gr6_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/589a/8907017/da8f5652ebd2/gr7_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/589a/8907017/eb5299e2de82/figs7_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/589a/8907017/91921f313ba0/fx1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/589a/8907017/299e87850f9c/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/589a/8907017/478947ac66fb/figs1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/589a/8907017/ac889e23fa0e/figs2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/589a/8907017/a64520bff288/figs3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/589a/8907017/92c738afc66e/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/589a/8907017/af819b6bfc41/figs4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/589a/8907017/3527d6ebddfb/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/589a/8907017/5983dc473a68/figs5_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/589a/8907017/c453dad92cca/figs6_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/589a/8907017/ead6264d32d4/gr4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/589a/8907017/665949210b77/gr5_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/589a/8907017/f389f11cd301/gr6_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/589a/8907017/da8f5652ebd2/gr7_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/589a/8907017/eb5299e2de82/figs7_lrg.jpg

相似文献

1
Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibody.吸入型双特异性单域抗体对 SARS-CoV-2 变体的广泛中和作用。
Cell. 2022 Apr 14;185(8):1389-1401.e18. doi: 10.1016/j.cell.2022.03.009. Epub 2022 Mar 10.
2
Structural Study of SARS-CoV-2 Antibodies Identifies a Broad-Spectrum Antibody That Neutralizes the Omicron Variant by Disassembling the Spike Trimer.SARS-CoV-2 抗体的结构研究鉴定出一种广谱抗体,通过分解 Spike 三聚体来中和奥密克戎变体。
J Virol. 2022 Aug 24;96(16):e0048022. doi: 10.1128/jvi.00480-22. Epub 2022 Aug 4.
3
A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.一种糖基化 RBD 蛋白诱导针对奥密克戎和其他变体的增强型中和抗体,提高对 SARS-CoV-2 感染的保护作用。
J Virol. 2022 Sep 14;96(17):e0011822. doi: 10.1128/jvi.00118-22. Epub 2022 Aug 16.
4
Novel bispecific human antibody platform specifically targeting a fully open spike conformation potently neutralizes multiple SARS-CoV-2 variants.新型双特异性人源抗体平台特异性靶向完全开放的刺突构象,能有效中和多种 SARS-CoV-2 变体。
Antiviral Res. 2023 Apr;212:105576. doi: 10.1016/j.antiviral.2023.105576. Epub 2023 Mar 2.
5
A novel bispecific antibody targeting two overlapping epitopes in RBD improves neutralizing potency and breadth against SARS-CoV-2.一种新型双特异性抗体靶向 RBD 中的两个重叠表位,提高了对 SARS-CoV-2 的中和效力和广度。
Emerg Microbes Infect. 2024 Dec;13(1):2373307. doi: 10.1080/22221751.2024.2373307. Epub 2024 Jul 12.
6
Neutralizing Ability of a Single Domain VNAR Antibody: In Vitro Neutralization of SARS-CoV-2 Variants of Concern.单域 VNAR 抗体的中和能力:体外对 SARS-CoV-2 关注变体的中和作用。
Int J Mol Sci. 2022 Oct 14;23(20):12267. doi: 10.3390/ijms232012267.
7
Human antibody BD-218 has broad neutralizing activity against concerning variants of SARS-CoV-2.人源抗体 BD-218 对 SARS-CoV-2 的关切变异株具有广泛的中和活性。
Int J Biol Macromol. 2023 Feb 1;227:896-902. doi: 10.1016/j.ijbiomac.2022.12.120. Epub 2022 Dec 14.
8
High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.新型冠状病毒刺突蛋白受体结合域线性表位在 COVID-19 mRNA 疫苗接种者中的高分辨率线性表位作图。
Microbiol Spectr. 2021 Dec 22;9(3):e0096521. doi: 10.1128/Spectrum.00965-21. Epub 2021 Nov 10.
9
Superimmunity by pan-sarbecovirus nanobodies.泛沙贝科病毒纳米抗体的超级免疫。
Cell Rep. 2022 Jun 28;39(13):111004. doi: 10.1016/j.celrep.2022.111004. Epub 2022 Jun 8.
10
Single-Domain Antibodies Efficiently Neutralize SARS-CoV-2 Variants of Concern.单域抗体高效中和关注的 SARS-CoV-2 变体。
Front Immunol. 2022 Feb 24;13:822159. doi: 10.3389/fimmu.2022.822159. eCollection 2022.

引用本文的文献

1
Antigenic and mutational insights into the Nipah virus G glycoprotein: implications for viral entry, host specificity, therapeutics, and vaccine development.尼帕病毒G糖蛋白的抗原性和突变研究:对病毒进入、宿主特异性、治疗方法及疫苗开发的启示
PeerJ. 2025 Aug 12;13:e19835. doi: 10.7717/peerj.19835. eCollection 2025.
2
Inhaled bispecific single-domain antibody BM219 for mild-to-moderate COVID-19: a double-blind, randomized, placebo-controlled phase 2 trial.吸入式双特异性单域抗体BM219用于治疗轻至中度新冠肺炎:一项双盲、随机、安慰剂对照的2期试验
Cell Discov. 2025 Jul 17;11(1):64. doi: 10.1038/s41421-025-00813-0.
3
Topical delivery of a human single-domain antibody targeting IL-33 to inhibit mucosal inflammation.

本文引用的文献

1
SARS-CoV-2 Omicron variant: Antibody evasion and cryo-EM structure of spike protein-ACE2 complex.SARS-CoV-2 奥密克戎变异株:刺突蛋白-ACE2 复合物的抗体逃逸和冷冻电镜结构。
Science. 2022 Feb 18;375(6582):760-764. doi: 10.1126/science.abn7760. Epub 2022 Jan 20.
2
Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2.奥密克戎变异株对 SARS-CoV-2 表现出明显的抗体逃逸。
Nature. 2022 Feb;602(7898):676-681. doi: 10.1038/s41586-021-04388-0. Epub 2021 Dec 23.
3
Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization.
局部递送靶向白细胞介素-33的人单域抗体以抑制黏膜炎症。
Cell Mol Immunol. 2025 Jun 11. doi: 10.1038/s41423-025-01305-7.
4
Construction and application of a large capacity VNAR library from the whitespotted bamboo shark ().来自点纹斑竹鲨的大容量VNAR文库的构建与应用。
Acta Pharm Sin B. 2025 Apr;15(4):1912-1921. doi: 10.1016/j.apsb.2025.02.012. Epub 2025 Feb 18.
5
Nanobodies: From Discovery to AI-Driven Design.纳米抗体:从发现到人工智能驱动的设计
Biology (Basel). 2025 May 14;14(5):547. doi: 10.3390/biology14050547.
6
Small but Mighty: Nanobodies in the Fight Against Infectious Diseases.小而强大:纳米抗体在抗击传染病中的作用
Biomolecules. 2025 Apr 23;15(5):610. doi: 10.3390/biom15050610.
7
Identification of a nanobody able to catalyze the destruction of the spike-trimer of SARS-CoV-2.一种能够催化破坏严重急性呼吸综合征冠状病毒2(SARS-CoV-2)刺突三聚体的纳米抗体的鉴定。
Front Med. 2025 May 3. doi: 10.1007/s11684-025-1128-4.
8
Nanoscale warriors against viral invaders: a comprehensive review of Nanobodies as potential antiviral therapeutics.对抗病毒入侵者的纳米级战士:关于纳米抗体作为潜在抗病毒疗法的全面综述
MAbs. 2025 Dec;17(1):2486390. doi: 10.1080/19420862.2025.2486390. Epub 2025 Apr 9.
9
Identification and characterization of a broadly neutralizing and protective nanobody against the HA1 domain of H5 avian influenza virus hemagglutinin.一种针对H5禽流感病毒血凝素HA1结构域的具有广泛中和活性和保护性的纳米抗体的鉴定与表征。
J Virol. 2025 May 20;99(5):e0209024. doi: 10.1128/jvi.02090-24. Epub 2025 Apr 7.
10
Application of pre-amplification-based CRISPR-Cas nanostructured biosensors for bacterial detection.基于预扩增的CRISPR-Cas纳米结构生物传感器在细菌检测中的应用。
Nanomedicine (Lond). 2025 Apr;20(8):903-915. doi: 10.1080/17435889.2025.2476384. Epub 2025 Mar 7.
奥密克戎能广泛但不完全地逃避辉瑞 BNT162b2 的中和作用。
Nature. 2022 Feb;602(7898):654-656. doi: 10.1038/s41586-021-04387-1. Epub 2021 Dec 23.
4
Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift.广谱中和抗体可克服 SARS-CoV-2 奥密克戎抗原漂移。
Nature. 2022 Feb;602(7898):664-670. doi: 10.1038/s41586-021-04386-2. Epub 2021 Dec 23.
5
Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies.奥密克戎逃避了大多数现有的 SARS-CoV-2 中和抗体。
Nature. 2022 Feb;602(7898):657-663. doi: 10.1038/s41586-021-04385-3. Epub 2021 Dec 23.
6
Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum.免疫后血清对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)奥密克戎B.1.1.529变体的中和作用降低。
Lancet. 2022 Jan 15;399(10321):234-236. doi: 10.1016/S0140-6736(21)02844-0. Epub 2021 Dec 20.
7
A non-ACE2 competing human single-domain antibody confers broad neutralization against SARS-CoV-2 and circulating variants.一种非 ACE2 竞争的人源单域抗体对 SARS-CoV-2 及流行变异株具有广泛中和作用。
Signal Transduct Target Ther. 2021 Nov 3;6(1):378. doi: 10.1038/s41392-021-00810-1.
8
Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study.定义由 SARS-CoV-2 抗体靶向的变异耐药表位:全球联盟研究。
Science. 2021 Oct 22;374(6566):472-478. doi: 10.1126/science.abh2315. Epub 2021 Sep 23.
9
Fc-engineered antibody therapeutics with improved anti-SARS-CoV-2 efficacy.具有提高的抗SARS-CoV-2疗效的Fc工程化抗体疗法。
Nature. 2021 Nov;599(7885):465-470. doi: 10.1038/s41586-021-04017-w. Epub 2021 Sep 21.
10
Live imaging of SARS-CoV-2 infection in mice reveals that neutralizing antibodies require Fc function for optimal efficacy.在小鼠中进行的 SARS-CoV-2 感染的活体成像研究表明,中和抗体需要 Fc 功能才能发挥最佳疗效。
Immunity. 2021 Sep 14;54(9):2143-2158.e15. doi: 10.1016/j.immuni.2021.08.015. Epub 2021 Aug 18.